Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.

Journal Article (Journal Article)

Glioblastomas extensively invade the surrounding normal brain tissue, with a concomitant expression of various proteolytic enzymes, in particular urokinase-type plasminogen activator (uPA). In this study we used cis-diamminedichloroplatinum (cisplatin) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), commonly used anti-cancer drugs for the treatment of glioblastomas, to study the expression of uPA in three human glioblastoma cell lines in vitro. Cells were treated with 25 microM cisplatin and 50 microM BCNU, and uPA levels were estimated by fibrin zymography during a 72-h time course. Treatment of glioblastoma cells with cisplatin resulted in significantly decreased levels of uPA in serum-free conditioned medium and cell extracts, compared to BCNU-treated and untreated cell lines. Quantitative levels of uPA enzyme activity assessed by scanning laser densitometry and uPA protein by ELISA using antibody against uPA showed decreased levels of uPA in cisplatin-treated glioma cell lines relative to BCNU and untreated cell lines. Our results suggest that anti-tumor compound, cisplatin, may exert its anti-neoplastic effects by inhibiting uPA in malignant glioblastomas.

Full Text

Duke Authors

Cited Authors

  • Go, Y; Chintala, SK; Rayford, A; Gagercas, E; Ali-Osman, F; Venkaiah, B; Sawaya, R; Gokaslan, Z; Nicolson, GL; Rao, JS

Published Date

  • July 1997

Published In

Volume / Issue

  • 15 / 4

Start / End Page

  • 447 - 452

PubMed ID

  • 9219734

International Standard Serial Number (ISSN)

  • 0262-0898

Digital Object Identifier (DOI)

  • 10.1023/a:1018462507706


  • eng

Conference Location

  • Netherlands